Watchlist Price Alert

Mineralys Therapeutics In... (MLYS)

NASDAQ: MLYS · Real-Time Price · USD

15.98

-0.34 (-2.08%)

At close: May 23, 2025, 3:59 PM

15.75

-1.44%

After-hours: May 23, 2025, 05:16 PM EDT

-2.08% (1D)

Bid	15.88
Market Cap	1.04B
Revenue (ttm)	n/a
Net Income (ttm)	-188.51M
EPS (ttm)	-3.75
PE Ratio (ttm)	-4.26
Forward PE	-4.88
Analyst	Buy

Ask	16.05
Volume	517,580
Avg. Volume (20D)	1,281,263
Open	15.98
Previous Close	16.32
Day's Range	15.86 - 16.68
52-Week Range	8.24 - 18.38
Beta	-0.31

About MLYS

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol MLYS

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for MLYS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

5 days ago

Mineralys Therapeutics shares are trading higher a... Unlock content with Pro Subscription

2 months ago

Mineralys Therapeutics shares are trading lower after the company announced a $175 million public offering.

News

3 days ago · zacks.com

Here's Why Momentum in Mineralys Therapeutics, Inc. (MLYS) Should Keep going

Mineralys Therapeutics, Inc. (MLYS) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

1 week ago · zacks.com

Here's Why Mineralys Therapeutics, Inc. (MLYS) is a Great Momentum Stock to Buy

Does Mineralys Therapeutics, Inc. (MLYS) have what it takes to be a top stock pick for momentum investors? Let's find out.

1 week ago · seekingalpha.com

Mineralys Therapeutics, Inc. (MLYS) Q1 2025 Earnings Conference Call Transcript

Mineralys Therapeutics, Inc. (NASDAQ:MLYS ) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants Dan Ferry - LifeSci Advisors, IR Jon Congleton - CEO Dave Rodman - Chief Medic...

3 weeks ago · 247wallst.com

Carl Icahn Buys More Shares, and Tesla Insider Bucks the Selling Trend

Insider buying has slowed considerably in the past week or so, due largely to the current first-quarter earnings reporting season.

2 months ago · 247wallst.com

Insiders Make Huge Purchases of These 4 Biotech Stocks

After a rough patch, it seems the biotech industry may be staging a comeback. Several biotech firms have gone public this year, and those focused on obesity treatments, gene therapies, and more have h...

2 months ago · benzinga.com

Hello Group, loanDepot, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

U.S. stock futures were higher this morning, with the Dow futures gaining around 200 points on Wednesday.

2 months ago · seekingalpha.com

Mineralys: Prospects Just Got Better With Successful Pivotal Data Readouts

Primary endpoints of both Advance-HTN and Launch-HTN studies, using lorundrostat to treat patients with hypertension were met with statistical significance. Upcoming catalysts include the full data re...

2 months ago · benzinga.com

Mineralys Therapeutics Unveils Positive Data From Two Trials For Hypertension Drug Candidate

On Monday, Mineralys Therapeutics, Inc. MLYS released topline data from its pivotal Launch-HTN Phase 3 and pivotal Advance-HTN Phase 2 trials of lorundrostat for uncontrolled hypertension (uHTN) or re...